• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

硫嘌呤类药物在炎症性肠病患者中具有长期疗效,与起始时的疾病持续时间无关:一项倾向评分匹配分析。

Thiopurines Have Sustained Long-term Effectiveness in Patients with Inflammatory Bowel Disease, Which is Independent of Disease Duration at Initiation: A Propensity Score Matched Analysis.

机构信息

Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, New Delhi, India.

Department of Radio Diagnosis, All India Institute of Medical Sciences, New Delhi, India.

出版信息

J Crohns Colitis. 2024 Feb 26;18(2):192-203. doi: 10.1093/ecco-jcc/jjad135.

DOI:10.1093/ecco-jcc/jjad135
PMID:37584328
Abstract

BACKGROUND AND AIMS

Thiopurines are viable option for the treatment of inflammatory bowel disease [IBD] in resource-limited countries. However, data on the effect of disease duration at thiopurines initiation on long-term effectiveness are limited.

METHOD

We performed a propensity matched analysis of a retrospective cohort of patients with ulcerative colitis [UC] and Crohn's disease [CD]. Patients initiated on thiopurines early in the disease course [≤2 years] were compared with those started late [>2 years]. Effectiveness was defined as no requirement for hospitalisation, anti-tumour necrosis factor [TNF] agents, or surgery, and minimum steroid requirement [≤1 steroid course in 2 years] during follow-up.

RESULTS

A total of 988 [UC: 720, CD: 268] patients were included (male: 665 [60.8%], median age: 40 [32-51] years, median follow-up: 40 [19-81] months). Overall effectiveness at 5 and 10 years was 79% and 72% in UC, and 69% and 63% in CD, respectively. After propensity score matching, there was no difference in 5- and 10-year effectiveness between early and late thiopurine initiation groups either for UC [81% and 80% vs 82% and 74%; p = 0.92] or CD [76% and 66% vs 72% and 51%, p = 0.32]. Male sex for UC (negative: hazard ratio [HR]: 0.67, 95% confidence interval [CI): 0.45-0.97; p = 0.03), and ileal involvement [positive: HR: 3.03, 95% CI: 1.32-6.71; p = 0.008], steroid-dependent disease [positive: HR: 2.70, 95% CI: 1.26-5.68; p = 0.01] and adverse events [negative: HR: 0.47, 95% CI:0.27-0.80; p = 0.005] for CD were predictors of thiopurine effectiveness.

CONCLUSION

Thiopurines have sustained long-term effectiveness in both UC and CD. However, early thiopurine initiation had no better effect on long-term disease outcome compared with late initiation.

摘要

背景和目的

硫嘌呤类药物是资源有限国家治疗炎症性肠病[IBD]的可行选择。然而,关于硫嘌呤类药物起始时疾病持续时间对长期疗效的影响的数据有限。

方法

我们对溃疡性结肠炎[UC]和克罗恩病[CD]患者的回顾性队列进行了倾向评分匹配分析。将疾病早期[≤2 年]开始使用硫嘌呤类药物的患者与疾病晚期[>2 年]开始使用硫嘌呤类药物的患者进行比较。疗效定义为在随访期间无需住院、使用抗肿瘤坏死因子[TNF]药物或手术,以及类固醇最低需求[2 年内≤1 个疗程类固醇]。

结果

共纳入 988 例[UC:720 例,CD:268 例]患者(男性:665 例[60.8%],中位年龄:40 [32-51]岁,中位随访时间:40 [19-81]个月)。UC 患者的 5 年和 10 年总有效率分别为 79%和 72%,CD 患者分别为 69%和 63%。在进行倾向评分匹配后,UC 患者的早期和晚期硫嘌呤类药物起始组在 5 年和 10 年的疗效方面无差异[81%和 80%与 82%和 74%;p=0.92],CD 患者也无差异[76%和 66%与 72%和 51%;p=0.32]。UC 患者的男性性别[负:风险比[HR]:0.67,95%置信区间[CI]:0.45-0.97;p=0.03],回肠受累[正:HR:3.03,95%CI:1.32-6.71;p=0.008],类固醇依赖疾病[正:HR:2.70,95%CI:1.26-5.68;p=0.01]和不良事件[负:HR:0.47,95%CI:0.27-0.80;p=0.005]是硫嘌呤类药物疗效的预测因素。

结论

硫嘌呤类药物在 UC 和 CD 中均具有长期疗效。然而,与晚期起始相比,早期起始硫嘌呤类药物对长期疾病结局没有更好的效果。

相似文献

1
Thiopurines Have Sustained Long-term Effectiveness in Patients with Inflammatory Bowel Disease, Which is Independent of Disease Duration at Initiation: A Propensity Score Matched Analysis.硫嘌呤类药物在炎症性肠病患者中具有长期疗效,与起始时的疾病持续时间无关:一项倾向评分匹配分析。
J Crohns Colitis. 2024 Feb 26;18(2):192-203. doi: 10.1093/ecco-jcc/jjad135.
2
Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn's disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource.硫唑嘌呤单药治疗在溃疡性结肠炎中有效,但在克罗恩病中效果显著降低:英国炎症性肠病生物资源中 11928 名患者的长期结局。
Gut. 2021 Apr;70(4):677-686. doi: 10.1136/gutjnl-2019-320185. Epub 2020 Oct 1.
3
Do Thiopurines Reduce the Risk of Surgery in Elderly Onset Inflammatory Bowel Disease? A 20-Year National Population-Based Cohort Study.硫唑嘌呤能否降低老年起病炎症性肠病的手术风险?一项基于全国人群的20年队列研究。
Inflamm Bowel Dis. 2017 Apr;23(4):672-680. doi: 10.1097/MIB.0000000000001031.
4
Impact of thiopurine discontinuation at anti-tumour necrosis factor initiation in inflammatory bowel disease treatment: a nationwide Danish cohort study.肿瘤坏死因子抑制剂治疗炎症性肠病时停用硫唑嘌呤的影响:一项全国性丹麦队列研究。
Aliment Pharmacol Ther. 2022 May;55(9):1128-1138. doi: 10.1111/apt.16777. Epub 2022 Jan 25.
5
Impact of early thiopurines on surgery in 2770 children and young people diagnosed with inflammatory bowel disease: a national population-based study.早期硫唑嘌呤对2770例诊断为炎症性肠病的儿童和青少年手术的影响:一项基于全国人群的研究。
Aliment Pharmacol Ther. 2015 Oct;42(8):990-9. doi: 10.1111/apt.13361. Epub 2015 Aug 13.
6
Minimal risk of lymphoma and non-melanoma skin cancer despite long-term use of thiopurines in patients with inflammatory bowel disease: A longitudinal cohort analysis from northern India.尽管在印度北部进行了纵向队列分析,但炎症性肠病患者长期使用硫嘌呤类药物,患淋巴瘤和非黑素瘤皮肤癌的风险仍然较低。
J Gastroenterol Hepatol. 2022 Aug;37(8):1544-1553. doi: 10.1111/jgh.15880. Epub 2022 May 10.
7
Relapse rates after withdrawal of thiopurines in patients with inflammatory bowel disease.炎症性肠病患者停用硫嘌呤后的复发率。
Int J Colorectal Dis. 2022 Aug;37(8):1817-1826. doi: 10.1007/s00384-022-04216-5. Epub 2022 Jul 14.
8
Poor Drug Sustainability in Inflammatory Bowel Disease Patients in Clinical Remission on Thiopurine Monotherapy.炎症性肠病患者在硫唑嘌呤单药治疗缓解期的药物可持续性差。
Dig Dis Sci. 2021 May;66(5):1650-1657. doi: 10.1007/s10620-020-06427-8. Epub 2020 Jun 26.
9
Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.在一项基于人群的队列研究中,与单药治疗相比,未接受过生物制剂治疗的患者采用 upfront 联合治疗与炎症性肠病相关并发症风险降低相关。
Clin Gastroenterol Hepatol. 2019 Aug;17(9):1788-1798.e2. doi: 10.1016/j.cgh.2018.11.003. Epub 2018 Nov 15.
10
Thiopurine Monotherapy Is Effective in Maintenance of Mild-Moderate Inflammatory Bowel Disease.硫唑嘌呤单药治疗可有效维持轻中度炎症性肠病。
Dig Dis Sci. 2022 Apr;67(4):1287-1294. doi: 10.1007/s10620-021-06947-x. Epub 2021 Mar 23.

引用本文的文献

1
Revisiting thiopurines and therapeutic drug monitoring in IBD: Insights and implications in the Indian context.重新审视硫唑嘌呤及炎症性肠病的治疗药物监测:印度背景下的见解与启示
Indian J Gastroenterol. 2025 Aug 29. doi: 10.1007/s12664-025-01864-7.
2
Inflammatory bowel disease in south Asia: a scoping review.南亚的炎症性肠病:一项范围综述。
Lancet Gastroenterol Hepatol. 2025 Mar;10(3):259-274. doi: 10.1016/S2468-1253(24)00341-8.
3
Utility of Tofacitinib in Steroid-Refractory Acute Severe Ulcerative Colitis.托法替布在激素难治性急性重症溃疡性结肠炎中的应用
Cureus. 2024 Oct 14;16(10):e71485. doi: 10.7759/cureus.71485. eCollection 2024 Oct.
4
Differences in the risk of clinical failure between thiopurine and methotrexate in bio-naïve patients with Crohn's disease: a Korean nationwide population-based study.初治克罗恩病患者中硫嘌呤与甲氨蝶呤临床治疗失败风险的差异:一项韩国全国性基于人群的研究
Therap Adv Gastroenterol. 2024 May 12;17:17562848241248321. doi: 10.1177/17562848241248321. eCollection 2024.
5
Uphill battle: Innovation of thiopurine therapy in global inflammatory bowel disease care. uphill battle:硫唑嘌呤治疗在全球炎症性肠病治疗中的创新。
Indian J Gastroenterol. 2024 Feb;43(1):36-47. doi: 10.1007/s12664-024-01529-x. Epub 2024 Feb 21.